Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010301
Filing Date
2025-05-14
Accepted
2025-05-14 16:30:23
Documents
47
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 482328
2 EX-10.1 ex10-1.htm EX-10.1 1783
3 EX-31.1 ex31-1.htm EX-31.1 10827
4 EX-31.2 ex31-2.htm EX-31.2 10952
5 EX-32.1 ex32-1.htm EX-32.1 3957
6 EX-32.2 ex32-2.htm EX-32.2 4005
7 GRAPHIC ex10-1_001.jpg GRAPHIC 570437
8 GRAPHIC ex10-1_002.jpg GRAPHIC 197767
  Complete submission text file 0001641172-25-010301.txt   3860906

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE mira-20250331.xsd EX-101.SCH 21199
10 XBRL CALCULATION FILE mira-20250331_cal.xml EX-101.CAL 25997
11 XBRL DEFINITION FILE mira-20250331_def.xml EX-101.DEF 98960
12 XBRL LABEL FILE mira-20250331_lab.xml EX-101.LAB 201467
13 XBRL PRESENTATION FILE mira-20250331_pre.xml EX-101.PRE 158598
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 322125
Mailing Address 324 SOUTH HYDE PARK AVENUE, SUITE 350 TAMPA FL 33606
Business Address 1200 BRICKELL AVENUE SUITE 1950 #1183 MIAMI FL 33131 813-369-5150
MIRA PHARMACEUTICALS, INC. (Filer) CIK: 0001904286 (see all company filings)

EIN.: 853354547 | State of Incorp.: FL
Type: 10-Q | Act: 34 | File No.: 001-41765 | Film No.: 25946243
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)